Aprea Therapeutics APRE
NASDAQ APRE
$0.72 -0.03 (-4.00%)
As of: Oct 1, 2026 · 3:59 PM EDT

Aprea Therapeutics (APRE) Current Deferred Revenue (2023 - 2024)

Updated

Aprea Therapeutics' Current Deferred Revenue was $50,739 in Q2 2024, down 65.8% from the prior quarter.

Analysis

Aprea Therapeutics (APRE) Current Deferred Revenue (2023 - 2024) Analysis & Trends

At the end of FY2023, Current Deferred Revenue at Aprea Therapeutics came in at $528,974.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Aprea Therapeutics 40.11 Mn 40.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 50,739.00
Mar 31, 2024 148,405.00
Dec 31, 2023 528,974.00
API Access

Aprea Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=APRE&period=max&api_key=YOUR_API_KEY